Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The French drug company posted better-than-expected fourth-quarter earnings on Friday and said it was targeting further cost cuts.

Sanofi Ramps Up Cost-Cutting as Earnings Beat Estimates. The Stock Is Rising.

Shares of Sanofi (NASDAQ:SNY) rose 2.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 3.33% over the past year to $1.45, which may not compare to the estimate of $0.69.

Sanofi: Q4 Earnings Insights

Sanofi SA (NASDAQ: SNY) posted a profit for the fourth quarter of 2020 at €1.08 billion, a turnaround from a loss of €10 million a year ago. However, sales came at €9.38 billion, down 2.4% year-over-year on a reported basis.

Sanofi Swings To Forth Quarter Profit Despite Lower Sales; Expands Cost-Savings Push By €500M

Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology

Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Sanofi (SNY)

Other big firms with no Covid-19 vaccine of their own may plan on helping manufacture competitors' vaccines, analysts say.

Sanofi Will Make Pfizer's Covid-19 Vaccine. Are More Partnerships Coming?

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Lockheed Martin

Altria

Merck

Roche Holding AG

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The February 2021 Heat Map

BioNTech SE

Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.

Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine

Pfizer

Unusual collaboration will see Sanofi supply more than 125 million doses of Pfizer–BioNTech COVID shot from the summer.

Sanofi teams up with BioNTech and Pfizer to help fix Europe's vaccine shortage

French drug maker Sanofi SA will manufacture 125 million doses of the COVID-19 vaccine co-developed by Pfizer Inc and BioNTech SE in its Frankfurt plant starting this summer.

Sanofi To Manufacture 125 Million COVID-19 Vaccine Doses For Rival Pfizer-BioNTech

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - December 2020

Capgemini SE

Orange

Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe

Press Release// Sanofi, Capgemini, Generali and Orange announce the creation of a digital ecosystem dedicated to e-health, a first in Europe

Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend. Dupixent and flu vaccine sales growth boosted revenue in the latest quarter and the deep drug pipeline is impressive.

Sanofi: Big Pharma Turnaround Trading At A Discount

Total

Unilever

Vanguard FTSE Europe ETF

Part 2 of the series will search the European market for value. Sanofi is a big pharma company trading at a low valuation and paying a 3.5% dividend.

Finding Value As We Near A Possible End To The Bull Market: European Markets

Sanofi recently announced that it is going to buy Kymab. These are the details.

Why Sanofi Is Buying Kymab For Up To $1.45 Billion

Sanofi (SNY) CEO Paul Hudson Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)

After divesting its active pharmaceutical ingredient segment, the slimmed-down company will have more time to focus on developing new blockbuster drugs.

Sanofi Spins Off an Industry-Leading Business

SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer

CSL Ltd

Their coronavirus projects fell behind, faltered, or failed.

3 Coronavirus Stocks to Stay Miles Away From in 2021

Heineken NV

The Invesco European Growth Fund (Trades, Portfolio) disclosed last week that its top five trades during the fiscal fourth quarter included new holdings in Heineken NV (XAMS:HEIA), TGS-NOPEC Geophysical Co. ASA (OSL:TGS) and Sanofi SA (NASDAQ:SNY)(XPAR:SAN). The fund also divested out of Allianz SE (XTER:ALV) and Essilorluxottica (XPAR:EL).

Invesco European Growth Fund's Top 5 Trades of the 4th Quarter

AbbVie

Bristol-Myers

Johnson & Johnson

Novartis

Takeda Pharmaceutical

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

The Top 7 Pharmaceutical Stocks for the Next 10 Years

Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.

Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence

French drugmaker Sanofi has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals as it belatedly expands in a fast-growing medical area.

Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L

News for Sanofi Stock (SNY)